Heike Prinz will join the Bayer Board of Management as Chief Talent Officer and Labor Director effective Sept. 1, 2023.
Bayer’s Supervisory Board has appointed Heike Prinz as Chief Talent Officer and Labor Director of the Leverkusen-based company. Previously, Sarena Lin and the Supervisory Board had mutually agreed not to extend Lin’s contract as a member of the Board of Management beyond Jan. 31, 2024. Lin has been a member of the Bayer Board of Management since Feb. 1, 2021. She will leave the company on Aug. 31, 2023.
Norbert Winkeljohann, Chairman of the Supervisory Board, thanked Sarena Lin “for her dedication, valuable input and the successful initiatives undertaken under her leadership – all of which helped to lay the foundation for Bayer and its people to unlock the full potential of the company in this new chapter. During her tenure, Sarena has shaped and advanced leadership capabilities within the organization, inspiring trust, loyalty and strong performance from employees at all levels while also championing diversity, equity and inclusion.” said Winkeljohann.
Heike Prinz (58) looks back on a career at Bayer spanning almost 37 years. She is currently Commercial Director of the Pharmaceuticals Division for Europe/Middle East/Africa and a member of the Pharmaceuticals Division Executive Committee. She began her career in November 1986 at Schering, the Berlin-based pharmaceutical company acquired by Bayer in 2006. Since then Prinz has held positions of increasing responsibility in sales, marketing, executive management, and administration.
Heike Prinz holds a master’s degree in business administration from the Berlin School of Economics and Law and has extensive experience in leading large organizations in different cultures. She has a strong track record in product launches, restructuring, sustainable business growth, and cultural change. Heike Prinz is married and has lived and worked in Germany, Singapore, Thailand, and Japan. She will be based in Leverkusen.
Source: chemanager-online.com
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
